James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

These Are Buys, Four-Digit P/E’s Be Damned!

By James Brumley, InvestorPlace Feature Writer Dec 21, 2012

Sometimes, an outrageously high valuation is worth the high price of entry -- as is true for these four stocks. Take a look at our four-digit P/E portfolio.

Accenture’s Dip: An Opportunity, Not an Omen

By James Brumley, InvestorPlace Feature Writer Dec 21, 2012

Sometimes, investors' first reactions to an earnings report can be off-track. Accenture's (slightly) disappointing quarter doesn't make this stock a loser.

Forget Alcoa — This Company Is a Better Earnings Barometer

By James Brumley, InvestorPlace Feature Writer Dec 20, 2012

Alcoa's results are often used as barometer of earnings success, but that’s an antiquated (and possibly dangerous) assumption. Here's who to watch instead.

What’s Next for Apple Stock? $600 … or $400?

By James Brumley, InvestorPlace Feature Writer Dec 19, 2012

Counterintuitive as it might be, the fact that analysts have gone sour on Apple stock might be the best indication that AAPL will be OK.

Chemical Stocks: 2 to Buy, 2 to Sell

By James Brumley, InvestorPlace Feature Writer Dec 17, 2012

Two chemical makers might be worth a swing right now before the spotlight shines on the sector again; two others should be avoided.

Big Pharma: 2012-13’s Flu Vaccine Field

By James Brumley, InvestorPlace Feature Writer Dec 13, 2012

Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.

The 5 Most Surprising Stock Stories of 2012

By James Brumley, InvestorPlace Feature Writer Dec 12, 2012

While the broader market had a fairly typical year, several stock stories caught the financial press completely off guard. Here's a look at five big surprises.

Why Netflix Should Raise Its Rates Now

By James Brumley, InvestorPlace Feature Writer Dec 10, 2012

Netflix has pleased customers with its Disney deal and a pledge to not raise rates. Really, though, now is the perfect time for the company to up its fee.

Stock Showdown: Wall Street’s Meat Elite

By James Brumley, InvestorPlace Feature Writer Dec 7, 2012

Months after the fact, meat stocks made it through the Midwest drought smelling like roses. But which is worth riding in the shadow of a bull run?

Sanity Check: Starbucks’ American Expansion

By James Brumley, InvestorPlace Feature Writer Dec 5, 2012

Considering the backlash after Starbucks' last great American over-expansion, news of 1,500 new stores in five years has many investors raising an eyebrow.